Abstract

OF THE INVENTION LOCAL ADMINISTRATION OF RIPK2 INHIBITORS FOR THE CURATIVE TREATMENT OF ALLERGIC ASTHMA The present invention relates to a method for use in the treatment of Asthma. Here, the inventors identified the receptor-interacting serine/threonione protein kinas 2 (RIPK2) as a novel therapeutic target to improve Asthma-related diseases. They demonstrated that a local preventive administration of the RIPK2 inhibitor reduced AHR, airway eosinophilia, mucus production, Th2 cytokines and the alarmin IL-33. Moreover, they demonstrated the early role of IL-33 in the NOD1-dependent response of the epithelium to HDM. Therefore, the inventors demonstrated that the local interference of the NOD1 signaling pathway through RIPK2 inhibition may represent a new therapeutic approach in asthma. Other pulmonary diseases could also benefit of this treatment. Thus, the present invention relates to a method for use in the curative treatment of HDM-induced asthma comprising administrating to a subject in need thereof a therapeutically effective amount of an inhibitor of RIPK2.

IPC Classes  ?

• A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
• A61K 31/47 - QuinolinesIsoquinolines
• A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
• A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 11/06 - Antiasthmatics
• A61P 37/08 - Antiallergic agents

Abstract

jijij2n-11n1nn).

IPC Classes  ?

• A61B 5/024 - Measuring pulse rate or heart rate
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons

Abstract

The present invention relates to the treatment of Tauopathies. In this study, the inventors worked on an optimized treatment of Tauopathies, including AD and primary Tauopathies. Previously, the inventors evidenced that Tau pathology is associated with deleterious T-cell-mediated processes that contribute to promote Tau-related detrimental neuroinflammation and cognitive deficits. Considering the unique capacity of immunosuppressive Tregs to inhibit both CD4+ and CD8+ T cell responses, the inventors raise the hypothesis that amplifying Tregs may allow controlling Tau-driven T-cell-mediated detrimental processes in the course of AD and other Tauopathies. They thus evaluated preclinically the impact on disease progression of an optimized IL-2-based Treg-targeting immunomodulatory treatment in the THY-Tau22 mouse model of Tauopathy. They chronically treated THY-Tau22 mice with an optimized IL-2-based treatment, i.e. complexes of IL-2 and anti-IL-2 antibodies (termed herein IL-2C) in order to modulate Tau-associated detrimental T cell responses. Their data supports that this treatment amplifies Tregs more efficiently and selectively than "regular" low dose IL-2 treatment. Furthermore, they hereby showed that IL-2C has a beneficial effect on cognitive deficits since treated THY-Tau22 mice tend to acquire and retain spatial information more potently than untreated littermates. Thus, the invention relates to an IL-2/anti-IL-2 complex (IL-2C) for use in the treatment of Tauopathies.

IPC Classes  ?

• C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
• A61K 38/20 - Interleukins
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The present application relates to pyrazole derivatives as PD-1/PD-L1 interaction inhibitors. The applicants designed compounds of general formula (I), wherein R', R2, y3, R3, R4, R5, R6and R7in vitroin vitro biological tests (FRET assay, Promega Blockade assay, T cell assay). These compounds had an affinity (Kd) of the order of pM that was higher than that of the antibody atezolizumab used in clinical use, and had a comparable or better IC50 than that observed with atezolizumab. Thus, the present invention also relates to a pharmaceutical composition comprising said compound(s) and their uses in the treatment of PD-1-PD-L1 interactions-related diseases (cancer, chronic inflammatory diseases, neurological diseases and chronic infections).

IPC Classes  ?

• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• A61P 35/00 - Antineoplastic agents
• C07D 231/40 - Acylated on said nitrogen atom
• C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 403/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing aromatic rings
• C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• A61K 31/415 - 1,2-Diazoles
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/5355 - Non-condensed oxazines containing further heterocyclic rings

Abstract

METHODS OF TREATMENT OF METABOLIC DISORDERS In the present invention SLC5A9 gene (encoding SGLT4 protein) regulation was analyzed in the intestine of patients before and after weight-loss surgery. RNA scope analysis was used to determine the precise location of SLC5A9 in the human intestine and pancreas. Sglt4 knock- out (KO) mice were created using CRISPR/Cas techniques, allowing to study changes in their metabolic phenotype for months while they were fed the WD (Western Diet). So, these data demonstrate that SLC5A9 mRNA levels are induced in the apical membrane of the intestine and exocrine pancreas in persons with obesity and Type 2 Diabetes. Furthermore, Sglt4 deficiency slows the onset of obesity and hyperglycemia in mice fed the WD, improving insulin sensitivity by improving beta cell function. Accordingly the present invention relates to a method for preventing or treating metabolic disorders by targeting the Sodium-Glucose-Co- Transporter-4 (SGTL4).

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C40B 30/06 - Methods of screening libraries by measuring effects on living organisms, tissues or cells
• G01N 33/15 - Medicinal preparations
• A61P 3/00 - Drugs for disorders of the metabolism
• A61P 3/04 - AnorexiantsAntiobesity agents
• A61P 3/08 - Drugs for disorders of the metabolism for glucose homeostasis
• A61P 5/48 - Drugs for disorders of the endocrine system of the pancreatic hormones
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys

Abstract

LDLrLDLr -/-PPARαLDLrLDLr -/- PPARαPPARα +/+LDLrLDLr -/- PPARαPPARα -/-LDLrLDLr -/- PPARαPPARα +/+LDLrLDLr -/- PPARαPPARα +/+LDLrLDLr -/- PPARαPPARα +/+ mice. The present invenion defines a new relevant mouse model of progressive MASLD, developing all the characteristics of human MASLD (steatosis, inflammation, ballooning, fibrosis), in a relatively short time period (12-18 weeks), along with simultaneous atherosclerosis development.

IPC Classes  ?

• A01K 67/0276 - Knock-out vertebrates

Abstract

Provided are closed systems methods of use for isolation of mammalian tissues.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues

Abstract

The invention concerns a new galenic formulation of CFT (clofoctol) allowing the administration of this antibiotic in aerosol form with the objective of treating pulmonary infections (COVID-19, influenza), cancer and inflammation thus targeting the diseased tissue while avoiding the problems of solubility of CFT and toxicity associated with this drug. This new formulation allows to answer these problems and concerns the development of polymeric nanoparticles (Nanoparticles) in suspension in an aqueous phase intended to be administrated in a form of aerosol or spray, said Nanoparticles comprising PLGA and PLGA-PEG polymers, allowing to obtain an effective encapsulation of CFT and a controlled release of CFT at the pulmonary level.

IPC Classes  ?

• A61K 9/51 - Nanocapsules

Abstract

The present invention proposes a method for manufacture of an endoprosthesis, in particular a vascular endoprosthesis, comprising the 3D printing (100) of a hollow membrane made of thermoplastic elastomer, and the fastening (200) of a collapsible metal framework to the hollow membrane in order to form a membrane-framework assembly. The fastening comprises (i) the 3D printing (201) of an additional membrane made of thermoplastic elastomer, the arranging (202) of the collapsible metal framework between the hollow membrane and the additional membrane in order to obtain an assembly, the immersion soaking (204) of the assembly in an organic solvent in order to obtain the membrane-framework assembly, and the drying (205) of the membrane-framework assembly; or (ii) the arranging (212) of the collapsible metal framework on the hollow membrane in order to obtain an assembly, and the dip coating (214) in a solution in an organic solvent, and then the drying (215) of the assembly.

IPC Classes  ?

• A61F 2/07 - Stent-grafts

Abstract

The present disclosure relates to conjugates of catechol-based siderophores with cargo molecules, such as antibiotics or fluorophores, and to the preparation and uses thereof.

IPC Classes  ?

• A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
• A61K 49/00 - Preparations for testing in vivo
• A61P 31/04 - Antibacterial agents
• C07D 211/94 - Oxygen atom, e.g. piperidine N-oxide
• C07D 223/12 - Nitrogen atoms not forming part of a nitro radical
• C07D 277/10 - Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
• C07D 323/00 - Heterocyclic compounds containing more than two oxygen atoms as the only ring hetero atoms
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
• C07D 413/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
• C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• C07D 473/18 - Heterocyclic compounds containing purine ring systems with oxygen, sulfur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
• C07D 473/34 - Nitrogen atom attached in position 6, e.g. adenine
• C07D 491/16 - Peri-condensed systems
• C07D 493/10 - Spiro-condensed systems
• C07D 498/08 - Bridged systems
• C07D 499/64 - Compounds with an amino radical acylated by carboxylic acids, attached in position 6 with a carbon chain, substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, attached to the carboxamido radical substituted in alpha-position to the carboxamido radical by nitrogen atoms

Abstract

Glutamatergic neurons produce, accumulate and release in synapses the neurotransmitter glutamate, which is the main excitatory neurotransmitter in the mammalian central nervous system. Said neurons are involved in most of the brain's fundamental processes such as cognition, learning, memory, and sensory perception. There is an interest to identify transcription factor that would allow the differentiation towards glutamatergic neurons. The inventors surprisingly show that overexpression of ASCL1 induces the generation of a highly pure population of glutamatergic neurons. Said observation goes totally in the opposite direction of what has been previously taught, since ASLC1 was mainly described as inducing GABAergic neurons in the forebrain. Therefore, the present invention relates to methods for generating highly pure glutamatergic neuronal populations using the pro-neural factor ASCL1.

IPC Classes  ?

• C12N 5/0793 - Neurons

Abstract

The present invention pertains to an inner ear implant for controlled release of an active ingredient comprising the active ingredient and polyethylene vinyl acetate (EVA).

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/20 - Pills, lozenges or tablets
• A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone

Abstract

The present disclosure relates to a controlled release delivery dosage form for controlled release of an active ingredient, comprising a core comprising said active ingredient, coated by a polymeric mixture of at least a water insoluble polymer, and at least a polysaccharide extract selected from the group consisting of aqueous aloe vera extract and aqueous reishi extract, their methods of producing and uses thereof.

IPC Classes  ?

• A61K 9/50 - Microcapsules
• A61K 31/606 - Salicylic acidDerivatives thereof having amino groups

Abstract

The gut-to-lung axis is critical during respiratory infections, including influenza A virus (IAV) infection. In the present study, the inventors used high-resolution shotgun metagenomics and targeted metabolomics analyses to characterize influenza-associated changes in the mouse gut microbiota's composition and metabolism. Quantitative targeted metabolomics analysis of serum revealed changes in specific classes of gut microbiota metabolites, including SCFAs, indole-containing tryptophan metabolites, trimethylamine, and polyamines. The changes in microbiota-associated metabolites were correlated with changes in taxon abundances and levels of disease markers. For instance, the tryptophan metabolite indole-3-propionic acid (IPA) was correlated positively with some Bacillota species but negatively with Bacteroidales bacteria M7, the viral load, and inflammation markers. Given its marked fall during infection, the inventors tested the effects of IPA supplementation in diseased animals. This supplementation was associated with a lower viral load and lower levels of local (lung) and systemic inflammation during influenza. Taken as a whole, the results highlighted IPA as both an important metabolic modulator to disease severity and a potential biomarker of influenza outcomes.

IPC Classes  ?

• A61K 31/405 - Indole-alkanecarboxylic acidsDerivatives thereof, e.g. tryptophan, indomethacin
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

The invention relates to a microfluidic device (1) for forming a cell assembly comprising at least one first cell (C1) and one second cell (C2) and for individually treating a selected cell of said cell assembly, comprising: - a microfluidic channel (10); - at least one main inlet (11) for a fluid containing first cells, respectively second cells, arranged in a first portion (101) of the microfluidic channel; - an outlet (12) arranged in a second portion (102) of the microfluidic channel for controlling a fluid flow rate in the microfluidic channel; - at least one first auxiliary inlet (131) for a first auxiliary fluid arranged in the first portion (101) of the microfluidic channel upstream or downstream of the main inlet (11); - at least one cell trap (14) arranged in the microfluidic channel between the first portion and the second portion, wherein each cell trap (14) comprises at least one first trapping portion (141) and one second trapping portion (142), each first and second trapping portion being sized to receive a respective first or second cell, said first and second trapping portions being adjacent to each other in a direction perpendicular to a bottom (100) of the microfluidic channel to form the cell assembly with the trapped first and second cells, each cell being at a different height relative to the bottom of the microfluidic channel, - at least one first valve for controlling a flow rate of the first auxiliary fluid so as to cause the fluid containing the first cells, respectively the second cells, to flow at a determined height in the microfluidic channel in order to bring the first cell, respectively the second cell, to the first trapping portion, respectively to the second trapping portion.

IPC Classes  ?

• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers

Abstract

Therapeutic resistance is one of the major challenges in cancer treatment. These latter may be inherently resistant or this resistance may be acquired during treatment. In this context, the tau protein, encoded by the MAPT gene, could prove to be an important contributor in resistance to cancer therapy. The inventors have been thus abled to confirm in vivo that the tau protein was a factor of resistance to radiotherapy and the chemotherapy inducing DSB (doxorubicin) and that the reduction of its expression by shRNA increased the sensitivity of tumors to these treatments. The present invention relates to a method for decreasing therapeutic acquired resistance to chemotherapy agent and/or radiotherapy agent in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a Tau inhibitor.

IPC Classes  ?

• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61P 35/00 - Antineoplastic agents
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• C12N 15/115 - Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith

Abstract

ApicomplexaToxoplasmaT. gondii T. gondii T. gondii morphology and inhibiting intracellular replication. The findings highlight the advantage of comparative and targeted phenotypic analysis involving two related parasite species as a means of identifying molecules with a conserved mode of action.

IPC Classes  ?

• C12Q 1/18 - Testing for antimicrobial activity of a material
• A61P 33/02 - Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
• A61K 31/00 - Medicinal preparations containing organic active ingredients
• C07K 14/45 - Toxoplasma
• C12N 1/10 - ProtozoaCulture media therefor
• C12N 15/09 - Recombinant DNA-technology
• G01N 21/00 - Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

BlastocystisBlastocystisBlastocystisBlastocystis sp. in fecal samples obtained from heifers, for predicting productive longevity in heifers, and for improving dairy herd management.

IPC Classes  ?

• C12Q 1/6893 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for protozoa

Abstract

The inventors have now succeeded in developing novel compounds comprising a diphenylpyrazole scaffold bearing amino side chains. These compounds have the advantage of repressing the production of Aβ1-x and modulating the ratio of autophagy markers with higher efficacy than chloroquine and compounds of the prior art, in particular compounds of the prior art, The present invention is thus directed to compounds of Formula (I) including their pharmaceutically acceptable salts and solvates which have the ability to repress the production of Aβ1-x peptides and to modulate the ratio of autophagy markers, and which are useful as therapeutic compounds, particularly in the treatment and/or prevention of diseases involving the formation of amyloid plaques and/or in which dysfunction of the APP metabolism occurs.

IPC Classes  ?

• A61K 31/415 - 1,2-Diazoles
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C07D 231/22 - One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms

Abstract

The present disclosure relates to a pharmaceutical injectable solution comprising dopamine or a pharmaceutically acceptable salt thereof, preferably dopamine hydrochloride, dissolved in water for injection, wherein the solution has a pH between 3.0 and 5.5, and has an oxygen content equal to or lower than 0.008% (8 ppm), and uses thereof.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/08 - Solutions
• A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine

Abstract

The present invention relates to a surgical insert (1) comprising a first layer (11), and a second layer (12), wherein the first layer and the second layer comprise orifices (111, 121) having an eight shape.

IPC Classes  ?

• A61F 2/30 - Joints
• A61B 17/60 - Surgical instruments or methods for treatment of bones or jointsDevices specially adapted therefor for osteosynthesis, e.g. bone plates, screws or setting implements for external osteosynthesis, e.g. distractors or contractors

Abstract

The present invention relates to a surgical insert (1) comprising a first layer (11) and a second layer (12), wherein the first layer and the second layer comprise openings (111, 112) having a figure-of-eight shape. The invention also relates to a bone cement comprising a pulverulent solid phase that comprises natural polysaccharides and a ceramic filler, a liquid acrylate, and a polymerising agent.

IPC Classes  ?

• A61F 2/30 - Joints
• A61L 27/10 - Ceramics or glasses
• B33Y 70/00 - Materials specially adapted for additive manufacturing

Abstract

Here the inventors applied PDAC-derived CAF secretome on pancreatic cancer cells and evaluated Sig-1R implication in stromal cues integration by PCC from signaling transmission to biological outcomes, at the cellular and physiological level. They demonstrated that the loss of Sig-1R in epithelial cells inhibits stromal-induced tumor growth and metastatic process. Thus, the inventors demonstrate that Sig-1R is a key actor of the dialog between stromal and cancer cell compartments The present invention relates to method for the treatment of pancreatic cancer in a patient in need thereof comprising a therapeutically effective amount of a Sig-1R ligand.

IPC Classes  ?

• A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61P 35/00 - Antineoplastic agents

Abstract

The present disclosure relates to a hydrogel composition based on anionic cyclodextrin polymers and chitosan for use in the treatment of articular disorders. In particular, the hydrogel combines a pharmacological action, in particular an analgesic action, with a visco- supplementation (a lubricating effect).

IPC Classes  ?

• A61L 27/26 - Mixtures of macromolecular materials
• A61L 27/52 - Hydrogels or hydrocolloids
• A61L 27/54 - Biologically active materials, e.g. therapeutic substances

Abstract

Chronic obstructive pulmonary disease is a major clinical challenge mostly due to cigarette smoke exposure and affects more than 200 million people. The inventors tested if exposure to the Bordetella pertussis BPZE1 stain could modulate outcomes of chronic exposure to cigarette smoke in mice. In particular, they showed in mice chronically exposed to cigarette smoke that preventive and/or curative vaccination using BPZE1 could limit the lung inflammation and strongly contribute to the prevention of lung function decline. BPZE1 vaccination modulated pulmonary antigen presenting cells (macrophages and dendritic cells) to switch the immune response, by decreasing the IL-17 inflammatory pathway involved in the pathology of COPD itself, and by favouring a tolerogenic response (IL-10). Together, the data show that vaccination with BPZE1 of mice chronically exposed to cigarette smoke limits the development of chronic obstructive pulmonary disease outcomes and thus represents an interesting therapy.

IPC Classes  ?

• A61K 39/02 - Bacterial antigens
• A61P 11/00 - Drugs for disorders of the respiratory system
• C12N 1/36 - Adaptation or attenuation of cells
• C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
• C07K 14/235 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Bordetella (G)
• A61K 35/74 - Bacteria
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• C12N 9/10 - Transferases (2.)
• C12N 9/16 - Hydrolases (3.) acting on ester bonds (3.1)
• C12R 1/01 - Bacteria or actinomycetales
• C12N 1/20 - BacteriaCulture media therefor

Abstract

Exacerbation of heart failure, better known as acute decompensated heart failure (HF), is characterized by dyspnea, edema and fatigue, and is a growing medical problem. The inventors demonstrated that transient O-GlcNAcase inhibition would be suitable for the treatment of acute decompensated heart failure. In particular they used two recently developed models mimicking acute decompensation of heart failure patients, and deciphered mechanisms susceptible to be involved in this cardiovascular protection, with a focus on post-translational cardiac protein modifications and metabolic remodeling. Accordingly, the present invention relates to the use of O-GlcNAcase inhibitors for the treatment of acute decompensated heart failure.

IPC Classes  ?

• A61K 31/429 - Thiazoles condensed with heterocyclic ring systems
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contractionDrugs for heart failure

Abstract

In the present invention, inventors demonstrate that prenatal excess of anti-Müllerian hormone triggers PCOS-like impairment in female sexual behavior in mice. Sexual dysfunction in PCOS-like mice is associated with decreased expression of neuronal nitric oxide synthase (nNOS) neurons in different hypothalamic regions known to be involved in female sexual behavior: rostral periventricular area of the third ventricle (RP3V), ventromedial nucleus of the hypothalamus (VMH), and arcuate nucleus (ARN) during estrus. Chemogenetic inhibition of nNOS neuronal activity in the ventromedial nucleus of the hypothalamus of control adult females recapitulates PCOS-like sexual dysfunction. Of clinical relevance, administration of nitric oxide (NO) donor rescues normal sexual behavior in PCOS-like mice. Accordingly, the present invention relates to invention relates to Nitric Oxyde (NO) agent for use in the prevention or the treatment of sexual dysfunction associated with Polycystic Ovary Syndrome (PCOS) or with Hypoactive Sexual Desire Disorder (HSDD) in a subject in need thereof.

IPC Classes  ?

• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• A61P 15/00 - Drugs for genital or sexual disordersContraceptives

Abstract

The invention relates to a device for trapping at least one cell pair in a solution containing at least one first cell (C1) of a first type and at least one second cell (C2) of a second type, comprising: - a microfluidic channel (3) adapted for a unidirectional flow (F) of the solution; - a first trap (1) comprising a pair of first fingers (10a, 10b) arranged in the microfluidic channel (3), at least one of said first fingers (10a, 10b) being coupled to a respective first actuator (11a, 11b), said first actuator being configured to adjust the first trap (1) along a direction transversal to the flow (F) between an open position allowing passage of the first cell between the first fingers (10a, 10b) and a closed position adapted to a size of the first cell to allow trapping the first cell between the first fingers (10a, 10b);15 - a second trap (2) comprising a pair of second fingers (20a, 20b) arranged in the microfluidic channel (3), at least one of said second fingers (20a, 20b) being coupled to a respective second actuator (21a, 21b), said second actuator being configured to adjust the second trap (2) along a direction transversal to the flow (F) between an open position allowing passage of the second cell between the second fingers (20a, 20b) and a closed position adapted to a size of the second cell to allow trapping the second cell between the second fingers (20a, 20b); wherein the first trap (1) is arranged relative to the second trap (2) so as to form, when the first and second traps are in the closed position, a cell pair comprising the trapped first and second cells such that the second cell is in physical or chemical interaction with the first cell.

IPC Classes  ?

• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers

Abstract

In the present invention inventors perform studies on extracellular vesicles isolated from urine samples to assess the biomarker potential of measures of the LRRK2-Rab pathway in idiopathic and LRRK2 linked PD as well as in inhibitor dosed rodents and non-human primates. Their results show modifications in the LRRK2-Rab pathway in urinary EVs, both in disease and after LRRK2 kinase inhibitor treatment. More preciasly inventors have found in a first cohort that pS1292-LRRK2 levels were elevated in individuals carrying the LRRK2 G2019S mutation, but did not differ significantly between healthy and PD groups, whether for LRRK2 G2019S carriers or not. In a second cohort, they found that PD was statistically associated to and increase in Rab8 levels and a decrease in S910-LRRK2 and S935-LRRK2 phosphorylation rates. This study assesses LRRK2 and Rabs as a disease and pharmacodynamic marker in human urine samples and this current analysis shows LRRK2 and Rab epitopes modified in patient groups.

IPC Classes  ?

• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

Cisplatin is a potent chemotherapeutic drug, widely used in the treatment of various solid cancers. However, its clinical effectiveness is strongly limited by frequent severe adverse effects, such as neuropathy. Therefore, there is an urgent medical need to identify novel strategies limiting cisplatin-induced pain. Here, the inventors provide evidence that the FDA-approved adenosine A2A receptor antagonist istradefylline (KW-6002) significantly protects from cisplatin-induced neuropathy in experimental models of sub-chronic cisplatin treatment. In particular, the present invention relates to a method for the treatment of neuropathy (e.g. CIPN) in a subject in need therefore comprising administering to the subject a therapeutically effective amount of a selective A2A Adenosine Receptor (A2AR) antagonist.

IPC Classes  ?

• A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
• A61K 33/243 - PlatinumCompounds thereof
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
• A61P 35/00 - Antineoplastic agents

Abstract

2A2A2A2AR) antagonist.

IPC Classes  ?

• A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 33/243 - PlatinumCompounds thereof
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to an adhesive composition comprising a calcium phosphate ceramic selected from tetracalcium phosphate and alpha-tricalcium phosphate, phosphorylated serine, polydopamine, and an aqueous solvent. The invention also relates to a kit, to a method for producing said adhesive composition as well as to the uses thereof.

IPC Classes  ?

• A61L 24/00 - Surgical adhesives or cementsAdhesives for colostomy devices

Abstract

Disclosed are modified cytokines which, relative to wild-type forms, comprise one or more amino acid modifications. Relative to the activity of wild type cytokines, these modified cytokines exhibit enhanced activity at an acidic pH and often reduced activity at neutral pH. The disclosed modified cytokines are for use in medicine and/or for the treatment and/or prevention of an immunological condition or cancer.

IPC Classes  ?

• C07K 14/55 - IL-2

Abstract

Agents for the treatment of patients having non-small cell lung cancer and methods of diagnostics related include an inhibitor of miR 24 3p, a locked nucleic acid, including methods of predicting response to platinum-based chemotherapy, for patients having, or suspected of having, non-small cell lung cancer.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 33/243 - PlatinumCompounds thereof
• A61P 35/00 - Antineoplastic agents
• A61P 11/00 - Drugs for disorders of the respiratory system
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

The present invention relates to a device for collecting a fraction of the perspiration excreted by a subject, said device being of the type comprising a multi-layer patch (1) comprising: - a first layer (61, 62, 4) comprising at least one perspiration-collecting aperture (611) and a transfer opening (41); - a hydrophilic absorbent layer (5), positioned above the first layer and communicating with the external environment, and communicating with the first layer via the transfer opening (41); - a film (7), possibly transparent, that constitutes a barrier against water and against vapour and that covers at least the upper face of the absorbent layer (5); said device notably comprising means (6) for regulating the rate at which perspiration in the liquid and/or vapour state penetrates the absorbent layer (5).

IPC Classes  ?

• A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 10/00 - Instruments for taking body samples for diagnostic purposesOther methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determinationThroat striking implements

Abstract

The present invention relates to a method for rapid detection or quantification of viral particles in a sample. This method is particularly useful for rapid test of SARS-CoV-2.

IPC Classes  ?

• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

The present invention relates to a pharmaceutical composition comprising propofol and at least one cyclodextrin and/or a cyclodextrin derivative. Characteristically, according to the invention, it further comprises at least one pharmaceutically acceptable salt, with the exception of basic and/or acidic pharmaceutically acceptable salts.

IPC Classes  ?

• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit

Abstract

The present invention relates to a device for detecting a pressure, of the type comprising a detection element on which a pressure is exerted, a transducer connected to said detection element and an elastically deformable shell. Characteristically, according to the invention, said shell (1) is made of biocompatible and sterilisable material, has two opposing walls (11; 19) and an insertion opening (13), and said detection element comprises at least one elastically deformable tube (7), said tube comprises a portion arranged in said shell (1), said tube is closed at one end (71) and filled with a fluid, the other end of said tube being open, arranged outside said shell (1) and connected to said transducer (3).

IPC Classes  ?

• A61B 17/00 - Surgical instruments, devices or methods
• A61B 17/44 - Obstetrical forceps

Abstract

The present invention relates to methods for detecting a target in a sample using mutated nanobodies, wherein an amino acid present in the loop of the FR1 region of framework of the nanobodies is mutated to cysteine.

IPC Classes  ?

• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• A61K 39/42 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum viral
• A61K 39/44 - Antibodies bound to carriers

Abstract

The invention is in the field of the treatment of non-small cell lung cancer. The invention provides agents for the treatment of patients having non-small cell lung cancer and methods of diagnostics related, including methods of predicting response to platinum-based chemotherapy, for patients having, or suspected of having, non-small cell lung cancer.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/7125 - Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
• C12N 15/87 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation

Abstract

The present invention concerns an in vitro method for diagnosing invasive candidiasis (IC) in a subject which comprises detecting the presence of a Candida glycan and detecting the presence of antibody directed against a protein selected from the group consisting of fructose bisphosphate aldolase (Fba1), enolase 1 (Eno1), heat shock protein 90 (Hsp90), hyphal wall protein (Hwp1), and mannoprotein 65 (Mp65) in a blood, plasma or serum sample of the subject. The invention also relates to a method of determining a suitable treatment regimen for a patient and to a kit for implanting the methods described herein.

IPC Classes  ?

• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses